Topical gel combo decreases severe pruritus, pain in shingles-related case

March 16, 2015

Study details how a topical gel helped bring “significant relief” to patient’s severe pain and itching. Find out how

Results of a Mayo Clinic study suggest that the addition of topical 2% amitriptyline / 0.5% ketamine gel to the usual multimodal therapy can help reduce both the pruritus and the pain associated with shingles.

In their case study, John R. Griffin, M.D., and Mark D.P. Davis, M.D., of the Mayo Clinic’s department of dermatology, note that while acute herpetic pain has been found to significantly affect health-related quality of life, no studies have attempted to measure the quality-of-life impact of herpetic pruritus. They also note that many drugs that alleviate neuropathic pain do not necessarily have the same effect on neuropathic itch in the individual patient.

The case study focuses on a 64-year-old man with Crohn’s disease who was admitted for enterocutaneous fistula takedown. He had no history of herpes zoster. During his postoperative stay, he had hyperalgesia, erythema, and vesicles with ipsilateral conjunctivitis and keratitis. He was treated with intravenous acyclovir. Varicella zoster virus was confirmed with polymerase chain reaction of blister fluid.

RELATED: Study: Little difference in shingles risk among RA biologics

Three days after the skin eruption, the patient reported itching in the area, a symptom that in two weeks became unrelenting severe pruritus and burning pain that the patient rated as 10/10 on the visual analog scale. Over three days, the pruritus extended to include the bilateral scalp, though the pain remained localized to the area of infection. Initial treatment recommendations included wound care with dilute acetic acid wet dressings and twice daily 2.5% hydrocortisone cream. The patient reported that he had a decrease in his symptoms that lasted several hours with this regimen. Oral gabapentin therapy was begun at a dosage of 300mg three times daily and was titrated to up to 400mg three times daily.

Low-dose oral opioid therapy was discontinued in favor of non-opioid analgesics, as opioids may cause considerable pruritus in some patients. Topical lidocaine patches were applied to intact surrounding skin every 12 hours. Therapy with oral hydroxyzine (25 mg daily) was started, but was used intermittently because of the patient’s concern about associated somnolence. After the combination of these interventions, the patient rated his itch at 7/10 or 8/10 for most of the day and 10/10 for the rest of the day.

Though the patient’s primary medical and surgical conditions had stabilized by this time, his pruritus and pain prohibited his dismissal. Treatment of conjunctivitis and keratitis consisted initially of erythromycin ophthalmic ointment. Unfortunately, he also had an immune stromal keratitis, which required the addition of ophthalmic corticosteroids.

NEXT: twice daily applications of topical 2% amitriptyline 

 

RELATED: Zoster vaccine effective in older chemotherapy patients

At this point, twice daily applications of topical 2% amitriptyline compounded with 0.5% ketamine in an organogel were added to the patient’s treatment regimen. The gel was initially applied only to the skin surrounding the affected area, but as the erosions healed the gel was applied to the area of herpetic infection.

Within four days of the initial treatment with the compound gel, the patient’s pruritus had decreased from 7/10 to 5/10. Pain levels were similarly affected. According to the study, the patient reported that treatment with topical 2% amitriptyline / 0.5% ketamine gel gave him significant relief.

RELATED: How to reduce, prevent herpes zoster

“The response of this patient's pain to the topical formulation of amitriptyline and ketamine suggests that this topical combination could be used for the skin pain associated with herpes simplex,” Dr. Davis tells Dermatology Times. “This formulation may decrease the necessity for systemic opioids for control of pain.”

The study appears in the February issue of Journal of Drugs in Dermatology